I'm LongbridgeAI, I can summarize articles.NRx Pharmaceuticals subsidiary HOPE Therapeutics has begun treating patients with major depressive disorder using Zeta Surgical’s FDA-cleared Zeta TMS Navigation System at two Florida clinics. This rollout integrates precision-guided outpatient TMS care into HOPE’s interventional psychiatry platform and supports NRX’s upcoming SPARC-TMS trial, which pairs NRX-101 with robotic-enabled TMS across civilian and military sites.
- NRX Pharmaceuticals subsidiary HOPE Therapeutics began treating patients using Zeta Surgical’s FDA-cleared Zeta TMS Navigation System at two Florida clinics. * Rollout moves HOPE’s interventional psychiatry platform into routine, precision-guided outpatient TMS care for major depressive disorder. * Deployment supports NRX’s planned SPARC-TMS trial pairing NRX-101 with robotic-enabled TMS across civilian and military treatment sites. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606250700PRIMZONEFULLFEED9752538) on June 25, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)